minodronic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium metabolism regulator, pharmaceutical aid | 4074 | 180064-38-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 11, 2011 | PMDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Atypical femur fracture | 70.68 | 30.61 | 17 | 911 | 4980 | 46680154 |
| Osteonecrosis of jaw | 65.98 | 30.61 | 25 | 903 | 34377 | 46650757 |
| Spinal compression fracture | 50.52 | 30.61 | 16 | 912 | 12887 | 46672247 |
| Hepatic function abnormal | 38.45 | 30.61 | 17 | 911 | 34404 | 46650730 |
| Upper respiratory tract inflammation | 31.85 | 30.61 | 8 | 920 | 2787 | 46682347 |
| Osteomyelitis | 31.40 | 30.61 | 13 | 915 | 22370 | 46662764 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
None
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Osteoporosis | indication | 64859006 | DOID:11476 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.11 | acidic |
| pKa2 | 6.18 | acidic |
| pKa3 | 7.16 | acidic |
| pKa4 | 10.96 | acidic |
| pKa5 | 11.56 | acidic |
| pKa6 | 5.65 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Farnesyl pyrophosphate synthase | Enzyme | IC50 | 8.52 | CHEMBL | |||||
| Geranylgeranyl pyrophosphate synthase | Enzyme | Ki | 5.74 | CHEMBL | |||||
| Geranylgeranyl pyrophosphate synthase | Enzyme | Ki | 6.89 | CHEMBL | |||||
| Farnesyl diphosphate synthase | Enzyme | IC50 | 5.96 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D09198 | KEGG_DRUG |
| C0662880 | UMLSCUI |
| M0N | PDB_CHEM_ID |
| CHEMBL319144 | ChEMBL_ID |
| DB06548 | DRUGBANK_ID |
| 3164 | IUPHAR_LIGAND_ID |
| 7651 | INN_ID |
| 40SGR63TGL | UNII |
| 130956 | PUBCHEM_CID |
Pharmaceutical products:
None